Daraxonrasib doubled median survival versus chemotherapy in metastatic pancreatic cancer phase 3 trial. Uses novel partner-protein strategy to target previously "undruggable" RAS oncogene effectively.
Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a ...
A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...
Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial. Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib ...
PENNSYLVANIA, USA — The polls across Pennsylvania closed at 8 p.m. on Tuesday, and election results began pouring in from across the state. This year, the race for U.S. Senate and Congressional seats ...
Newark Mayor Ras J. Baraka won a fourth term leading New Jersey’s largest city on Tuesday, based on unofficial results. Baraka received 70.3% of the votes cast with all 173 districts reporting, ...
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...
Shares of Erasca Inc. (NASDAQ:ERAS) tumbled to $9.02, down $10.13, or 52%, on phase I dose-escalation data with ERAS-0015, a potentially best-in-class, pan-RAS molecular glue, in RAS-mutant solid ...
AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results